A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects

Nerve growth factor (NGF) has emerged as a key driver of pain perception in several chronic pain conditions, including osteoarthritis (OA), and plays an important role in the generation and survival of neurons. Although anti-NGF antibodies improve pain control and physical function in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Yukari Koya, Hirotsugu Tanaka, Eiji Yoshimi, Nobuaki Takeshita, Shuji Morita, Hiroki Morio, Kanako Mori, Hiroshi Fushiki, Masazumi Kamohara
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2022.2149055
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849468027188281344
author Yukari Koya
Hirotsugu Tanaka
Eiji Yoshimi
Nobuaki Takeshita
Shuji Morita
Hiroki Morio
Kanako Mori
Hiroshi Fushiki
Masazumi Kamohara
author_facet Yukari Koya
Hirotsugu Tanaka
Eiji Yoshimi
Nobuaki Takeshita
Shuji Morita
Hiroki Morio
Kanako Mori
Hiroshi Fushiki
Masazumi Kamohara
author_sort Yukari Koya
collection DOAJ
description Nerve growth factor (NGF) has emerged as a key driver of pain perception in several chronic pain conditions, including osteoarthritis (OA), and plays an important role in the generation and survival of neurons. Although anti-NGF antibodies improve pain control and physical function in patients with clinical chronic pain conditions, anti-NGF IgGs are associated with safety concerns such as effects on fetal and postnatal development and the risk of rapidly progressive osteoarthritis. To overcome these drawbacks, we generated a novel anti-NGF PEGylated Fab’ antibody. The anti-NGF PEGylated Fab’ showed specific binding to and biological inhibitory activity against NGF, and analgesic effects in adjuvant-induced arthritis model mice in a similar manner to an anti-NGF IgG. In collagen-induced arthritis model mice, the anti-NGF PEGylated Fab’ showed higher accumulation in inflamed foot pads than the anti-NGF IgG. In pregnant rats and non-human primates, the anti-NGF PEGylated Fab’ was undetectable in fetuses, while the anti-NGF IgG was detected and caused abnormal postnatal development. The PEGylated Fab’ and IgG also differed in their ability to form immune complexes in vitro. Additionally, while both PEGylated Fab’ and IgG showed analgesic effects in sodium monoiodoacetate-induced arthritic model rats, their effects on edema were surprisingly quite different. While the anti-NGF IgG promoted edema over time, the anti-NGF PEGylated Fab’ did not. The anti-NGF PEGylated Fab’ (ASP6294) may thus be a potential therapeutic candidate with lower risk of adverse effects for various diseases in which NGF is involved such as OA and chronic back pain.
format Article
id doaj-art-1d317d9198cb4f5ca6596cc78d7ab4ae
institution Kabale University
issn 1942-0862
1942-0870
language English
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series mAbs
spelling doaj-art-1d317d9198cb4f5ca6596cc78d7ab4ae2025-08-20T03:25:59ZengTaylor & Francis GroupmAbs1942-08621942-08702023-12-0115110.1080/19420862.2022.2149055A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effectsYukari Koya0Hirotsugu Tanaka1Eiji Yoshimi2Nobuaki Takeshita3Shuji Morita4Hiroki Morio5Kanako Mori6Hiroshi Fushiki7Masazumi Kamohara8Drug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanIncubation Lab, Astellas Innovation Management LLC, Cambridge, MA, USADrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanDrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanDrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanDrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanDrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanDrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanDrug Discovery Research, Astellas Pharma Inc, Tsukuba, JapanNerve growth factor (NGF) has emerged as a key driver of pain perception in several chronic pain conditions, including osteoarthritis (OA), and plays an important role in the generation and survival of neurons. Although anti-NGF antibodies improve pain control and physical function in patients with clinical chronic pain conditions, anti-NGF IgGs are associated with safety concerns such as effects on fetal and postnatal development and the risk of rapidly progressive osteoarthritis. To overcome these drawbacks, we generated a novel anti-NGF PEGylated Fab’ antibody. The anti-NGF PEGylated Fab’ showed specific binding to and biological inhibitory activity against NGF, and analgesic effects in adjuvant-induced arthritis model mice in a similar manner to an anti-NGF IgG. In collagen-induced arthritis model mice, the anti-NGF PEGylated Fab’ showed higher accumulation in inflamed foot pads than the anti-NGF IgG. In pregnant rats and non-human primates, the anti-NGF PEGylated Fab’ was undetectable in fetuses, while the anti-NGF IgG was detected and caused abnormal postnatal development. The PEGylated Fab’ and IgG also differed in their ability to form immune complexes in vitro. Additionally, while both PEGylated Fab’ and IgG showed analgesic effects in sodium monoiodoacetate-induced arthritic model rats, their effects on edema were surprisingly quite different. While the anti-NGF IgG promoted edema over time, the anti-NGF PEGylated Fab’ did not. The anti-NGF PEGylated Fab’ (ASP6294) may thus be a potential therapeutic candidate with lower risk of adverse effects for various diseases in which NGF is involved such as OA and chronic back pain.https://www.tandfonline.com/doi/10.1080/19420862.2022.2149055NGFPEGylated antibodyfabarthritispainplacental transfer
spellingShingle Yukari Koya
Hirotsugu Tanaka
Eiji Yoshimi
Nobuaki Takeshita
Shuji Morita
Hiroki Morio
Kanako Mori
Hiroshi Fushiki
Masazumi Kamohara
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects
mAbs
NGF
PEGylated antibody
fab
arthritis
pain
placental transfer
title A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects
title_full A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects
title_fullStr A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects
title_full_unstemmed A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects
title_short A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects
title_sort novel anti ngf pegylated fab provides analgesia with lower risk of adverse effects
topic NGF
PEGylated antibody
fab
arthritis
pain
placental transfer
url https://www.tandfonline.com/doi/10.1080/19420862.2022.2149055
work_keys_str_mv AT yukarikoya anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT hirotsugutanaka anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT eijiyoshimi anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT nobuakitakeshita anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT shujimorita anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT hirokimorio anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT kanakomori anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT hiroshifushiki anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT masazumikamohara anovelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT yukarikoya novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT hirotsugutanaka novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT eijiyoshimi novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT nobuakitakeshita novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT shujimorita novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT hirokimorio novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT kanakomori novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT hiroshifushiki novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects
AT masazumikamohara novelantingfpegylatedfabprovidesanalgesiawithlowerriskofadverseeffects